A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Lung | Melanoma, skin
What is the purpose of this trial?
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab. TIL as a single-therapy will be evaluated with LN-145 only.
- Trial withIovance Biotherapeutics
- Start Date07/13/2021
- End Date12/01/2023
- Last Updated07/19/2021
- Study HIC#2000023142